Skip Navigation

Home > Safety of low dose cannabidiol.

Therapeutic Goods Administration. (2020) Safety of low dose cannabidiol. ACT, Australia: Australian Government Department of Health. 25 p.

[img]
Preview
PDF (Safety of low dose cannabidiol.)
306kB

URL: https://www.tga.gov.au/alert/review-safety-low-dos...

Cannabidiol (CBD), a cannabinoid derived from the Cannabis plant, is being supplied as a medicine in Australia, but often as a component of oils and extracts of cannabis. A purified product has recently been approved for treatment of certain paediatric epilepsies in the US and is under regulatory evaluation in Australia as a registered medicine. There is increasing use, patient demand and health care practitioner interest in its use in clinical practice, as well as widespread use in over the counter medicines, complementary medicines and cosmetics in some countries.


Item Type
Evidence resource
Drug Type
Cannabis
Intervention Type
AOD disorder, AOD disorder drug therapy
Date
April 2020
Pages
25 p.
Publisher
Australian Government Department of Health
Corporate Creators
Therapeutic Goods Administration
Place of Publication
ACT, Australia
EndNote

Repository Staff Only: item control page